The UK and US have established a key trade agreement that will keep no levies on UK pharmaceutical shipments being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to increase spending on medicines through the public health system. This pledge secures that duties on these crucial exports will stay at nothing for a duration of 36 months.
This agreement follows earlier statements to hike import taxes on branded pharmaceutical imports, with potential rates discussed up to 100%.
"This agreement between the UK reinforces the international landscape for innovative medicines and brings much-needed balance to transatlantic drug exports," a statement said.
Commercial Importance
Medicines represent one of the Britain's largest export categories to the United States, which is clearly the primary buyer for major UK drugmakers.
Trade data indicate that in the one-year period to the end of last September, the UK sold pharmaceutical products worth £11.1bn to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This guarantee protects jobs, boosts investment and facilitates the UK to emerge as a international leader for medical research," a government official stated.
Detailed UK Commitments
The pact entails several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a goal to double overall public funding on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must pay back to the NHS to stay within budget will be limited at 15%. Previously, refunds were more than 20%.
Recent Tensions
This agreement comes amid a protracted dispute between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
This friction were heightened by arguments that American consumers were paying several times more for the same drugs than patients in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been pledged toward American operations.
One official stated that the NHS had to spend more on drugs, noting that its spending on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
